DIVI S LABORATORIES LTD Share price

Divi's Laboratories Limited is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals. The Company is one of the world's largest API companies, with two manufacturing units and a market presence across 100 countries. It is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports. Presently, it works 6 manufacturing units and market presence across several countries. The company has two subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products and to provide a greater reach to customers within these regions. The company has Research Centers at Sanathnagar, Hyderabad and at the manufacturing sites. Research Centre at Sanathnagar primarily focuses on custom synthesis, contract research for MNC companies as also future generics involving processes like route design, route selection, establishing gram scale process and structural confirmation. Divi's Laboratories Limited was established in year 1990 as Divis Research Center Limited (DRC) with Research & Development as their prime fundamental. In 1994, they changed their name to Divis Laboratories Limited to reflect their growing area of operations. During the year 1991-93, the company developed several commercial processes for intermediates and bulk actives and supplies to manufacturing majors. In the year 1995, the company started operations in their manufacturing facility (Unit I) at Choutuppal near Hyderabad. In the year 1997, the company was certified as ISO-9002 compliant by SGS-Yarsley of U.K. In the year 1999, European Directorate gave a 'Certificate of Suitability' (CoS) for Naproxen produced by the company. In the year 2001, the company received OHSAS-18001 Certification from BVQI of London for their Occupational Health and Safety Management Systems. In the year 2002, the company commenced setting up of their second manufacturing facility (Unit II) at Chippada near Visakhapatnam. In the year 2003, they opened a new research center christened 'DRC-Vizag' for fundamental research in selected niche business core segments. The company went for initial public offering (IPO) and their shares were listed on Bombay Stock Exchange and National Stock Exchange. In the year 2004, the company invested an amount of Rs 3035.21 lakh towards capital expenditure at their manufacturing facilities at Choutuppal (Unit-I) and Chippada (Unit-II) for additional machinery installed at both Unit-I and Unit-II. In the year 2006, the company received letter of approval from Ministry of Commerce, Government of India, for setting up a sector-specific special economic zone (SEZ) for pharmaceutical ingredients at Chippada, Bheemunipatnam in Visakhapatnam with investment of Rs 200 crore. The company's second manufacturing site at Chippada, was converted into Export Oriented Unit (EOU) and started operations as EOU from June 1, 2006. During the year 2006-07, the company developed an SEZ titled 'Divi's Pharma SEZ' on a 250-acre site at Chippada, Visakhapatnam. During the year 2007-08, the company set up new production as well as utility facilities in SEZ and EOU Units, and enhanced existing capacities at Unit-1. They commissioned Nutraceuticals Manufacturing facility at Divi's Pharma SEZ and commenced commercial operations effective June 1, 2008. During the year 2008-09, the company added 9 products to their product portfolio of which 4 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates. During the year 2009-10, they added 7 products to their product portfolio of which 2 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates. During the year 2010-11, the company added 21 products to their product portfolio of which 8 are generic APIs and intermediates and 13 are custom synthesis APIs and intermediates. The company set up a new facility called 'DSN SEZ Unit' at Chippada in Visakhapatnam at an estimated cost of Rs 200 crore for creating additional capacities for the new opportunities in generic as well as custom synthesis segment. The DSN SEZ Unit commenced commercial operations from June 1, 2011. During the year 2012-13, the company added 9 products to its product portfolio of which 3 are generic APIs and intermediates and 6 are custom synthesis APIs and intermediates. In 2014, the Korean Food and Drug Administration (KFDA) carried out inspection of the company's Visakhapatnam Unit-2 for the third time. During the year, fourth US FDA inspection was carried out at the company's Visakhapatnam Unit-2. Also during the year, fifth US FDA inspection was carried out for Unit-1. During the year, COFEPRIS (Mexico) inspected the company's Visakhapatnam Unit-2 for the first time. COFEPRIS (Mexico) also inspected the company's Choutuppal Unit-1 in Telangana for the first time in the year 2014. On 19 February 2016, Divi's Laboratories announced that it has had a successful inspection by the US-FDA for its Unit-2 at Chippada, Bheemunipatnam near Visakhapatnam during February 2016 with no observations. The Board of Directors of Divi's Laboratories at its meeting held on 12 August 2016 approved and ratified one-time ex-gratia of an aggregate amount of Rs 79 crore to the employees and whole-time directors of the company on the occasion of completion of 25 years of formation of the company. On 8 April 2017, Divi's Laboratories announced that the US-FDA has exempted some more products manufactured at the company's Unit-II at Visakhapatnam from import alert issued under clauses 66-40 and 99-32 of the FDA regulations. On 22 April 2017, Divi's Laboratories announced that the US-FDA has issued a warning letter for the company's Unit-II at Visakhapatnam. On 4 August 2017, Divi's Laboratories announced that the inspection of the Unit-2 Visakhapatnam was completed successfully by HPRA (Ireland) and JAZMP (Slovenia). The inspection was focused on follow up on the effectiveness of the CAPA implemented from the last JAZMP inspection and general GMP inspection of the site. On 15 November 2017, Divi's Laboratories announced that the US-FDA has lifted/removed import alert 66-40 imposed on the company's Unit-II at Visakhapatnam. On 18 November 2017, Divi's Laboratories announced that the company has received an Establishment Inspection Report (EIR) from US-FDA for Unit-II at Visakhapatnam, as closure of audit by FDA. On 16 May 2018, Divi's Laboratories announced that its Unit-I at Choutuppal, Telangana has had an inspection by the US-FDA from 14th May 2018 to 16th May, 2018. This was a general cGMP inspection by the FDA. The inspection has been concluded with no 483 observations. As on 31 March 2018, the company has two overseas subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products. During the year 2017-18, the company is making capacity additions at the existing manufacturing facilities and in this process we are building 2 additional production blocks at Unit-1 at Choutuppal. Capital WIP as at the year-end amounted to Rs 11976 lakhs. Capital expenditure incurred at the existing Units is to enhance capacities as well as upgrading utilities and infrastructure for compliances. As the company has significant accumulation of cash reserves, all capex has been funded with internal accruals. In order to cater to the increasing opportunities in generic and big pharma business, the Company during the FY2019, is taking up following two brownfield projects with an aggregate investment of Rs 1200 crore.a. An SEZ Unit at our Unit-II at Visakhapatnam, named as DCV SEZ Unit, with an investment of Rs 600 crore. (revised from the estimate of Rs 400 crore announced at the last General Meeting),b. Another SEZ Project with an investment of Rs 600 crore in the available land at our Unit-I in Bhuvangiri-Yadadri (erstwhile Nalgonda) District, Telangana State. The Company has commenced commercial operations from a part of the DC-SEZ Unit in February, 2020, and from a part of the DCV-SEZ Unit in March 2020. The Company has also taken up debottlenecking programs at Unit-I as well as Unit-II by investing an aggregate amount of Rs 300 crore -which would also create additional capacities for existing products. In addition, the company also taken up augmentation of waste treatment infrastructure at Unit-II at an estimated cost of Rs 150 crore. A part of the backward integration, debottlenecking and utility expansion projects have come into utilization this year. The rest of these projects will be completed and come into utilization by end of second half of financial year 2020-21. The balance works of the brownfield projects of DC-SEZ and DCVSEZ are also expected to be completed by second half of financial year 2020-21. As on 31 March 2020, the company has two overseas subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products. Eventhough there was a nationwide lockdown restrictions due to COVID-19 pandemic since March 24, 2020, the Government has exempted manufacturing units of essential goods including drugs and pharmaceuticals, medical devices, their raw materials and intermediates from the lockdown restrictions, amongst others. The Company has been operating in compliance with the various advisories/ guidelines passed by the Government of India, State Governments and statutory institutions. The new brownfield DC and DCV SEZ Units and the debottlenecking / backward integration programs taken up by the company during the last year, have become fully operational during the FY2021. Also Modernization and upgradation of waste water treatment plants at the manufacturing sites has been implemented. In April, 2023, Company setup a manufacturing plant (Unit-III) at Kakinada District of Andhra Pradesh. The Kakinada (Unit 3) project, operational since January 2025, has scaled up in phases through production of materials and intermediates at existing units in FY 2026. Unit 3 facility in Kakinada became a central hub for backward integration, with six blocks operational and two more under construction during FY26. The Company opened its Peptide Centre of Excellence in Peptide Division in 2026.